Management of Irritable Bowel Syndrome

Introduction

• Irritable Bowel Syndrome (IBS) is a chronic gastrointestinal disorder that requires a comprehensive management approach, including pharmacological and non-pharmacological interventions, as recommended by the American Gastroenterological Association and the British Society of Gastroenterology 1, 2

Pharmacological Treatment

• The American Gastroenterological Association (AGA) suggests using antispasmodics like dicyclomine in patients with IBS (conditional recommendation, low certainty in evidence) 3
• Antispasmodics provide greater global relief of IBS symptoms compared to placebo, and demonstrate improvement in abdominal pain (RR, 0.74; 95% CI, 0.59–0.93) 3
• Antispasmodics like dicyclomine and mebeverine are appropriate first-line agents for abdominal pain in IBS, with benefit mainly for abdominal pain and distension (18% and 14% over placebo) but minimal effect on bowel alterations, and a number needed to treat (NNT) of 5-7 4, 1
• The American Gastroenterological Association and British Society of Gastroenterology recommend tricyclic antidepressants (TCAs) as effective second-line agents when antispasmodics fail, with TCAs having a NNT of 4 for IBS pain and being particularly effective for pain-predominant symptoms 4, 2
• Low-dose TCAs, such as amitriptyline 10-50mg at night, address both pain perception and gut motility issues through central pain modulation, peripheral anticholinergic effects, and influence on gut serotonin pathways 4
• The following table summarizes the recommended treatments for IBS:

• Common side effects of dicyclomine include dry mouth (33%), dizziness (40%), blurred vision (27%), nausea (14%), and somnolence (9%), which are anticholinergic in nature 2
• Eluxadoline should be discontinued in patients who develop severe constipation, and alosetron has safety concerns such as history of serious adverse events including ischemic colitis and complications of constipation 1, 3
• Rifaximin has a favorable safety profile, but has limitations such as limited effect on abdominal pain 5

Non-Pharmacological Treatment

• Implementing a structured approach to identify food triggers and considering a trial of low FODMAP diet under dietitian supervision can help manage IBS symptoms, with a strength of evidence not specified in the article 4, 2
• Gradually increasing soluble fiber (3-4g/day initially) can also be beneficial in managing IBS symptoms 4, 2
• First-line dietary advice should include soluble fiber (e.g., ispaghula) started at a low dose (3-4 g/day) and gradually increased 2
• Combining pharmacological treatments with dietary modifications (low FODMAP diet) may provide better symptom control, as suggested by the National Institute of Diabetes and Digestive and Kidney Diseases 2
• Cognitive behavioral therapy (CBT) and gut-directed hypnotherapy can be used for global symptom management in IBS patients, with a moderate strength of evidence 2, 6
• Mindfulness-based stress reduction helps with psychological stress and negative emotions in patients with IBS, with a moderate strength of evidence 6
• Regular exercise is recommended for all IBS patients, including those with IBS-D, to help manage symptoms 2

Monitoring and Follow-up

• Allow 3-4 weeks for full effect of TCAs before assessing response, and response to treatment should be evaluated after 3-6 weeks 4, 2
• Monitor for anticholinergic side effects (dry mouth, constipation, blurred vision) and explain to patients that low doses are used for pain modulation, not for depression 4
• Assess for symptom improvement after 2-4 weeks of therapy, and monitor for anticholinergic side effects, particularly in elderly patients 2
• Patients with IBS-D should be monitored regularly, especially when initiating new treatments, to assess response and adjust therapy as needed 2

Special Considerations

• Continuing the same antispasmodics when they've already failed is unlikely to provide benefit, and inadequate trial period of TCAs can lead to underestimation of efficacy 4, 1
• Overlooking dietary factors can hinder effective management of IBS symptoms, and missing warning signs can lead to delayed diagnosis of other underlying pathologies 4, 1
• Elderly patients require careful consideration due to increased sensitivity to anticholinergic effects, and patients with glaucoma, urinary retention, or prostatic hypertrophy should avoid dicyclomine treatment 2
• Patients with a history of pancreatitis, sphincter of Oddi problems, cholecystectomy, or alcohol dependence should avoid eluxadoline treatment, and patients with a history of serious adverse events should avoid alosetron treatment 3